Professor Lu Wei from the Department of Pain from the Affiliated Cancer Hospital of Guizhou Medical University, Professor Xu Jing from the Department of Oncology of the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Dr. Chen Jiang, Chief Physician of the Department of Anorectal Medicine of the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Professor Li Xuesong from the Department of Oncology of Qixingguan District People's Hospital and many other experts gathered together to conduct in-depth discussions and exchanges on the progress of multidisciplinary cancer treatment.

The opening ceremony was delivered by Huang Jun, director of Qiannan Prefecture Hospital of Traditional Chinese Medicine. The content of this conference covered many aspects such as "non-drug treatment of refractory cancer pain", "clinical application of NOTES, Noses and TUES technology in abdominal surgery", "gynecological tumor and heredity", "comprehensive treatment of malignant tumors" and other aspects. With the development of this meeting, Mengyang Pharmaceutical Co., Ltd. brought the company's flagship product "Shengbai Oral Liquid (Mixture)" to the meeting.

During the meeting, Professor Xu Jing from the Department of Oncology of the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine shared the "Clinical Research Progress of Shengbai Oral Liquid" at the meeting. As a treatment drug for leukopenia caused by radiotherapy and chemotherapy for cancer, Shengbai Oral Liquid (Mixture) has been included in the 2020 edition of the Chinese Pharmacopoeia, and is a recommended therapeutic drug for the 13th Five-Year Plan innovative textbook "Hematology", national clinical pathways, diagnosis and treatment guidelines, and expert consensus. It has a clear effect on the prevention and treatment of bone marrow suppression after chemotherapy and radiotherapy in cancer patients, and also has a clear effect on improving the clinical symptoms of patients such as dizziness, fatigue, chills, cold limbs, and soreness in the waist and knees. Based on the results of modern pharmacological research, Professor Xu Jing gave a vivid and specific explanation of the mechanism of action of Shengbai Oral Liquid (Mixture), and through the report of the results of preclinical research and post-marketing re-evaluation RCT studies, the experts at the meeting had a deep understanding of the effectiveness and safety of the product. The conference had a strong academic atmosphere, heated discussions and enthusiastic responses.

This conference gathered multidisciplinary oncology diagnosis and treatment experts, and conducted professional chemistry Xi and discussion through the treatment methods, treatment progress and guideline interpretation of refractory cancer pain, digestive tumors, gynecological tumors, and adverse reactions of tumor treatment. The success of this conference will further improve the level of diagnosis and treatment of cancer treatment in the region, and will also be a blessing for many cancer patients!